Q3 2026 AngioDynamics Inc Earnings Call Transcript
Key Points
- AngioDynamics Inc (ANGO) reported strong top-line growth, particularly in the Med Tech segment, which saw a 19% increase in revenue.
- The company raised its full-year guidance for net sales and adjusted EBITDA for the third consecutive quarter, indicating strong performance and confidence in future growth.
- The Auryon platform achieved its 19th consecutive quarter of double-digit year-over-year growth, showcasing its strong market position and technological superiority.
- The mechanical thrombectomy business, including AlphaVac and AngioVac, grew approximately 18% over the prior year, driven by strong clinical performance and increased hospital adoption.
- NanoKnife saw a 21% increase in revenue, supported by expanded European indications and positive feedback from physicians, indicating strong market potential and adoption.
- Gross margin decreased by 110 basis points year-over-year, primarily due to tariffs, inflation, and costs associated with manufacturing transitions.
- The company reported an adjusted net loss of $3 million for the quarter, indicating ongoing financial challenges despite revenue growth.
- Tariff expenses are expected to be between $4 million and $6 million for the full fiscal year 2026, impacting profitability.
- The company anticipates using $3 million to $5 million of cash to build inventory due to upcoming sterilization vendor shutdowns, potentially affecting cash flow.
- Despite strong revenue growth, the adjusted loss per share guidance remains in the range of $0.30 to $0.23, reflecting continued financial pressure.
Good morning, and welcome to the AngioDynamics fiscal year 2026 third-quarter earnings call. (Operator Instructions) As a reminder, this conference call is being recorded.
The news release detailing AngioDynamics' fiscal 2026 third-quarter results crossed the wire earlier this morning and is available on the company's website. This conference call is also being broadcast live over the Internet at the Investors section of the company's website at www.angiodynamics.com. A webcast replay of the call will be available at the same site approximately one hour after the end of today's call.
Before we begin, I'd like to caution listeners that during the course of this conference call, the company will make projections or forward-looking statements regarding future events, including statements about expected revenue, adjusted earnings and gross margins for fiscal year 2026 as well as trends that may continue. Management incurs encourages you to review the company's past and future filings with the SEC, including, without
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
